Sustained expression of inflammatory monocytes and activated T cells in COVID-19 patients and recovered convalescent plasma donors.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
12 2021
Historique:
received: 01 05 2021
accepted: 18 05 2021
pubmed: 8 8 2021
medline: 18 11 2021
entrez: 7 8 2021
Statut: ppublish

Résumé

Intense monocyte activation and infiltration into the target tissues are the main mechanisms of lung injury in severe acute respiratory syndrome coronavirus 2 infection. A reduction in the degree and nature of such cellular responses is expected following recovery. We aimed to investigate the immune responses in moderate coronavirus disease 2019 (COVID-19) patients and recovered patients. Moderate COVID-19 patients (n = 34) at Lok Nayak Hospital, New Delhi, and COVID-19 recovered patients (n = 15) from the mild disease who were considered for convalescent plasma (COPLA) donation at the Institute of Liver and Biliary Sciences, New Delhi and healthy individuals (n = 10), were recruited. We have assessed 21 plasma cytokines using cytokine bead array, performed proteomics on serum proteins, and analyzed immune cells using a detailed multicolor flow cytometry. A significant increase in inflammatory markers such as macrophage inflammatory protein (MIP)1-α, monocyte chemotactic protein-1, macrophage migration inhibitory factor, vascular endothelial growth factor-A, and Leptin was observed in the moderate patients. Nonsurvivors additionally showed increased interleukin (IL)-6 levels. Consistently, the proteomics analysis showed the signatures of cytokine production and interferon-γ response, and increased level of acute-phase protein SAA1 in the serum of COVID-19 patients. Despite the sustained expression of MIPs, the recovered COPLA donors showed a surge in MCSF and IL-18 levels. Both the groups had increased CCR2, CX3CR1 positive monocytes, low CD8 Patients who have recovered and considered for COPLA donations still have compromised immunity with sustained expression of inflammatory monocytes and activated T cells.

Identifiants

pubmed: 34363351
doi: 10.1002/iid3.476
pmc: PMC8427128
doi:

Substances chimiques

Vascular Endothelial Growth Factor A 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1279-1290

Informations de copyright

© 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

Heliyon. 2020 Dec 31;7(1):e05877
pubmed: 33437888
J Infect Dis. 2020 Jun 11;221(12):1948-1952
pubmed: 32319519
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2393-402
pubmed: 27078110
J Immunol. 2011 Feb 1;186(3):1809-15
pubmed: 21191073
World J Gastroenterol. 2020 Sep 21;26(35):5287-5301
pubmed: 32994688
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Immun Inflamm Dis. 2021 Dec;9(4):1279-1290
pubmed: 34363351
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Leukoc Biol. 2021 Jan;109(1):13-22
pubmed: 33040384
Emerg Microbes Infect. 2020 Dec;9(1):558-570
pubmed: 32172672
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Metabolites. 2020 May 07;10(5):
pubmed: 32392884
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
J Infect. 2020 Jun;80(6):646-655
pubmed: 32277967
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880
pubmed: 32274301
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Genome Med. 2021 Apr 20;13(1):64
pubmed: 33879239
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cell Host Microbe. 2020 Jun 10;27(6):879-882.e2
pubmed: 32359396
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090

Auteurs

Ravinder Singh (R)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Hamed Hemati (H)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Meenu Bajpai (M)

Department of Transfusion Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Pushpa Yadav (P)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Ashish Maheshwari (A)

Department of Transfusion Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Suresh Kumar (S)

Department of Medicine, Lok Nayak Jai Prakash Hospital, New Delhi, India.

Sonal Agrawal (S)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Jayesh Kumar Sevak (JK)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Mojahidul Islam (M)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Jaswinder Singh Mars (JS)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Shiv K Sarin (SK)

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Nirupama Trehanpati (N)

Laboratory of Molecular Immunology, Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences, New Delhi, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH